Volume : 10, Issue : 04, April – 2023
Title:
39.MEDICAL OUTCOMES OF PARATHYROIDECTOMY
Authors :
Naif Abdulaziz Meighrbl
Abstract :
Hyperparathyroidism (HPT) is considered an endocrine disorder characterized by the hyperfunctioning of one or more parathyroid tissues and overproduction of the parathyroid hormone – a polypeptide hormone with 84 amino acids.Prolonged over-secretion of parathyroid hormone causes an elevation in serum calcium levels. HPT presents with a wide range of moderate to severe symptoms and no symptoms at all. Some common symptoms indicated of HPT include musculoskeletal symptoms (loss of muscle strength, painful joints), gastrointestinal issues (constipation), and neuropsychiatric symptoms (depression, anxiety, mood disorders, fatigue). Parathyroidectomy is considered the only curative and definitive option for treating HPT with high success rates. In parathyroidectomy, the overactive parathyroid tissues, involving one or more of the four parathyroid glands, are removed surgically. This surgical procedure aims to remove hyperplasia or adenoma(s) by exploring all of the four parathyroid glands with an overproduction of parathyroid hormone. Although parathyroidectomy is a safe procedure, some serious medical outcomes may still arise. This review article explores the common outcomes associated with parathyroidectomy, including postoperative hypocalcemia, hypoparathyroidism, hematoma, laryngeal nerve injury, prolonged length of stay, and recurrent HPT. To minimize serious medical outcomes of parathyroidectomy, a team of healthcare professionals, including surgeons, nursing staff, anesthesiologists, pathologists, and radiologists must be established.
Keywords: Hyperparathyroidism, parathyroidectomy, serum calcium, parathyroid hormone, recurrent HPT.
Cite This Article:
Please cite this article in press Naif Abdulaziz Meighrbl et al, Medical Outcomes Of Parathyroidectomy., Indo Am. J. P. Sci, 2023; 10 (04).
Number of Downloads : 10
References:
[1] Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, et al. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–9. https://doi.org/10.1210/jc.2014-1413.
[2] Greenspan BS, Dillehay G, Intenzo C, Lavely WC, O’Doherty M, Palestro CJ, et al. SNM Practice Guideline for Parathyroid Scintigraphy 4.0. J Nucl Med Technol 2012;40:111 LP – 118. https://doi.org/10.2967/jnmt.112.105122.
[3] Zavatta G, Clarke BL. Normocalcemic Hyperparathyroidism: A Heterogeneous Disorder Often Misdiagnosed? JBMR Plus 2020;4:e10391. https://doi.org/https://doi.org/10.1002/jbm4.10391.
[4] Bollerslev J, Schalin-Jäntti C, Rejnmark L, Siggelkow H, Morreau H, Thakker R, et al. Unmet therapeutic, educational and scientific needs in parathyroid disorders: Consensus Statement from the first European Society of Endocrinology Workshop (PARAT). Eur J Endocrinol 2019;181:P1–19. https://doi.org/10.1530/EJE-19-0316.
[5] Yeh MW, Ituarte PHG, Zhou HC, Nishimoto S, Amy Liu I-L, Harari A, et al. Incidence and Prevalence of Primary Hyperparathyroidism in a Racially Mixed Population. J Clin Endocrinol Metab 2013;98:1122–9. https://doi.org/10.1210/jc.2012-4022.
[6] Griebeler ML, Kearns AE, Ryu E, Hathcock MA, Melton LJ, Wermers RA. Secular trends in the incidence of primary hyperparathyroidism over five decades (1965–2010). Bone 2015;73:1–7. https://doi.org/https://doi.org/10.1016/j.bone.2014.12.003.
[7] Oberger Marques J V, Moreira CA. Primary hyperparathyroidism. Best Pract Res Clin Rheumatol 2020;34:101514. https://doi.org/https://doi.org/10.1016/j.berh.2020.101514.
[8] Wilkinson B, Wan Muhamad Hatta SF, Garnham A, Buch HN. Recurrent primary hyperparathyroidism: A diagnostic and management dilemma. Endocrinol Diabetes Metab Case Reports 2021;2021. https://doi.org/10.1530/EDM-20-0136.
[9] Lambert LA, Shapiro SE, Lee JE, Perrier ND, Truong M, Wallace MJ, et al. Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg 2005;140:374–82. https://doi.org/10.1001/archsurg.140.4.374.
[10] Majcen M, Hocevar M. Surgical options in treating patients with primary hyperparathyroidism. Radiol Oncol 2020;54:22–32. https://doi.org/10.2478/raon-2020-0010.
[11] Shalaby M, Hadedeya D, Lee GS, Toraih E, Kandil E. Impact of Surgeon-Performed Ultrasound on Treatment of Thyroid Cancer Patients. Am Surg 2020;86:1148–52. https://doi.org/10.1177/0003134820945229.
[12] Wilhelm SM, Wang TS, Ruan DT, Lee JA, Asa SL, Duh Q-Y, et al. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. JAMA Surg 2016;151:959–68. https://doi.org/10.1001/jamasurg.2016.2310.
[13] Rodriguez M. 42 – Parathyroidectomy. In: Nissenson AR, Fine RN, Mehrotra R, Zaritsky JBT-H of DT (Sixth E, editors. Handb. Dial. Ther. (Sixth Ed., New Delhi: Elsevier; 2023, p. 381–8. https://doi.org/https://doi.org/10.1016/B978-0-323-79135-9.00042-2.
[14] Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol 2018;13:952–61. https://doi.org/10.2215/CJN.10390917.
[15] Dulfer RR, Franssen GJH, Hesselink DA, Hoorn EJ, van Eijck CHJ, van Ginhoven TM. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg 2017;104:804–13. https://doi.org/10.1002/bjs.10554.
[16] Tang JA, Friedman J, Hwang MS, Salapatas AM, Bonzelaar LB, Friedman M. Parathyroidectomy for tertiary hyperparathyroidism: A systematic review. Am J Otolaryngol 2017;38:630–5. https://doi.org/https://doi.org/10.1016/j.amjoto.2017.06.009.
[17] Dulfer RR, van Ginhoven TM, Geilvoet W, de Herder WW, van Eijck CHJ. Operative Treatment of Primary Hyperparathyroidism in Daycare Surgery. Scand J Surg 2014;104:196–9. https://doi.org/10.1177/1457496914557015.
[18] Thomas DC, Roman SA, Sosa JA. Parathyroidectomy in the Elderly: Analysis of 7313 Patients1. J Surg Res 2011;170:240–6. https://doi.org/10.1016/j.jss.2011.03.014.
[19] Stefanova D, Ullmann TM, Limberg J, Moore M, Beninato T, Zarnegar R, et al. Risk Factors for Prolonged Length of Stay and Readmission After Parathyroidectomy for Renal Secondary Hyperparathyroidism. World J Surg 2020;44:3751–60. https://doi.org/10.1007/s00268-020-05711-y.
[20] Mueller M, Ebrahimi F, Christ E, Nebiker CA, Schuetz P, Mueller B, et al. Safety of parathyroidectomy in older vs. younger patients with primary hyperparathyroidism. Endocr Connect 2021;10:1273–82. https://doi.org/10.1530/EC-21-0363.
[21] Sinha S, Fok M, Ahmad I, Al-Sheikh M, Backhouse C. Shortening postoperative stay after parathyroidectomy – A District General Hospital experience. Int Arch Otorhinolaryngol 2020;24:313–8. https://doi.org/10.1055/s-0039-1698777.
[22] Shirali AS, Wu SY, Chiang YJ, Graham PH, Grubbs EG, Lee JE, et al. Recurrence after successful parathyroidectomy—Who should we worry about? Surg (United States) 2022;171:40–6. https://doi.org/10.1016/j.surg.2021.06.035.
[23] Mazotas IG, Yen TWF, Doffek K, Shaker JL, Carr AA, Evans DB, et al. Persistent/Recurrent Primary Hyperparathyroidism: Does the Number of Abnormal Glands Play a Role? J Surg Res 2020;246:335–41. https://doi.org/10.1016/j.jss.2019.08.007.
[24] Mallick R, Nicholson KJ, Yip L, Carty SE, McCoy KL. Factors associated with late recurrence after parathyroidectomy for primary hyperparathyroidism. Surg (United States) 2020;167:160–5. https://doi.org/10.1016/j.surg.2019.05.076.
[25] Ma T-L, Hung P-H, Jong I-C, Hiao C-Y, Hsu Y-H, Chiang P-C, et al. Parathyroidectomy Is Associated with Reduced Mortality in Hemodialysis Patients with Secondary Hyperparathyroidism. Biomed Res Int 2015;2015:639587. https://doi.org/10.1155/2015/639587.
[26] Singh Ospina NM, Rodriguez-Gutierrez R, Maraka S, Espinosa de Ycaza AE, Jasim S, Castaneda-Guarderas A, et al. Outcomes of Parathyroidectomy in Patients with Primary Hyperparathyroidism: A Systematic Review and Meta-analysis. World J Surg 2016;40:2359–77. https://doi.org/10.1007/s00268-016-3514-1.
[27] Kim SM, Long J, Montez-Rath ME, Leonard MB, Norton JA, Chertow GM. Rates and outcomes of parathyroidectomy for secondary hyperparathyroidism in the United States. Clin J Am Soc Nephrol 2016;11:1260–7. https://doi.org/10.2215/CJN.10370915.
[28] Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol 2015;10:90–7. https://doi.org/10.2215/CJN.03520414.
[29] De La Cruz Rodríguez IE, García Montesinos ES, Rodríguez-Delgado MF, Vargas Ortega G, Hernández LB, Zubieta VM, et al. Delayed Calcium Normalization after Successful Parathyroidectomy in Primary Hyperparathyroidism. Case Rep Endocrinol 2021;2021:1–4. https://doi.org/10.1155/2021/5556977.
[30] Del Rio P, Rossini M, Montana CM, Viani L, Pedrazzi G, Loderer T, et al. Postoperative hypocalcemia: analysis of factors influencing early hypocalcemia development following thyroid surgery. BMC Surg 2019;18:25. https://doi.org/10.1186/s12893-019-0483-y.
[31] Tayyebi-Khosroshahi H, Farnood F, Ghorbanian M, Karkon-Shayan F, Naghavi-Behzad M. Persistent hypocalcemia and hungry bone syndrome after parathyroidectomy and renal transplantation in a patient with end-stage renal disease. Niger Med J 2017;58:50. https://doi.org/10.4103/0300-1652.218416.
[32] Joliat G-R, Guarnero V, Demartines N, Schweizer V, Matter M. Recurrent laryngeal nerve injury after thyroid and parathyroid surgery: Incidence and postoperative evolution assessment. Medicine (Baltimore) 2017;96:e6674.